Designed by: Mohsin Shaikh
Produced by: Harshita
Shares of Gland Pharma plummeted nearly 20% on Monday, taking its two-day fall to 34%. Gland Pharma share price fell to an intraday low of Rs 861 on NSE, down 19.15% from the previous close of Rs 1,065
The fall in Gland Pharma share price comes after the company's March quarter profit plunged 72% YoY due to soft demand production shutdown at one of its facilities in Telangana
Gland Pharma's revenue declined by 28% to Rs 785 crore in Q4FY23 from Rs 1,103 crore in Q4FY22. The lower revenue base impacted EBITDA margins, which declined from 32% in Q4FY22 to 21% in Q4FY23
Gland Pharma said the production line shut down in Q4FY23 in the Pashamylaram Penems facility due to line upgradation and reduced business from the domestic B2C division along with softer off-take in the rest-of-the-world (ROW) market due to tender seasonality affected its revenues
Nomura India, which has a target of Rs 1,157 with a 'Neutral' rating on Gland Pharma stock, said the company has refrained from providing any guidance on revenue growth and Ebitda margin. This brokerage has cut its earnings estimates by 15-17% for FY24 and FY25
Brokerage firm Motilal Oswal has a buy rating on Gland Pharma stock with a target price of Rs 1,460. It cut its earnings by 22-36% for FY24 and FY25 factoring in reduction in scope of business from a bankrupt customer, gradual revival in business due to shift of business by another customer to alternate supplier, and reduced share of profit due to higher competition in existing product portfolio
"While the multiple headwinds on revenue and operational cost have hit its FY23 performance, we expect a slow recovery over the next 12-15M aided by new launches in China/other regulated markets, newer contracts in CDMO segment and inventory rationalization of existing products," said Motilal Oswal on Gland Pharma stock
However, Kotak Institutional Equities has a much bearish outlook for Gland Pharma as it downgraded the stock to 'sell' along with a cut of over 19% fair value to Rs 1,075. Despite Gland’s near-term outlook being challenging, the brokerage believes the lack of visibility regarding normalcy in sales and margins is a bigger worry
Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of Business Today. Investors should consult their financial advisors before taking any position